The effect of atypical antipsychotic medications in individuals with anorexia nervosa: A systematic review and meta-analysis

International Journal of Eating Disorders

Volumn 46, Issue 4, 2013, Pages 332-339

  Lebow, Jocelyn ^a   Sim, Leslie A ^a   Erwin, Patricia J ^a   Murad, M Hassan ^a  

^a MAYO CLINIC   (United States)

Author keywords

anorexia nervosa; atypical antipsychotic; meta analyses

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOMIPRAMINE; FLUOXETINE; OLANZAPINE; PLACEBO; RISPERIDONE;

ANOREXIA NERVOSA; ANXIETY; BODY MASS; BODY WEIGHT; COMPARATIVE EFFECTIVENESS; EATING DISORDER; FOLLOW UP; HUMAN; MENTAL DISEASE; META ANALYSIS; OUTPATIENT; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; SYSTEMATIC REVIEW; WEIGHT GAIN;

ADULT; ANOREXIA NERVOSA; ANTIPSYCHOTIC AGENTS; BODY WEIGHT; HUMANS; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 84876033997     PISSN: 02763478     EISSN: 1098108X     Source Type: Journal    
DOI: 10.1002/eat.22059     Document Type: Review

References (27)

1. Hoek H,. Incidence, prevalence and mortality of anorexia nervosa and other eating disorders. Curr Opin Psychiatry 2006; 19: 389-394.
2. Steinhausen H,. The outcome of anorexia nervosa in the 20th century. Am J Psychiatry 2002; 159: 1284-1293.
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Arlington: American Psychiatric Association; 2000.
4. Kaye WH, Frank GK, Bailer UF, Henry SE,. Neurobiology of anorexia nervosa: Clinical implications of alterations of the function of serotonin and other neuronal systems. Int J Eat Disord 2005; 37: 15-19.
5. Court A, Mulder C, Kerr M, Yuen HP, Boasman M, Goldstone S, et al. Investigating the effectiveness, safety and tolerability of quetiapine in the treatment of anorexia nervosa in young people: A pilot study. J Psychiatr Res 2010; 44: 1027-1034.
6. Allison D, Mentore J, M. H, Chandler L, Cappelleri J, Infante M, Weiden P,. Antipsychotic-induced weight gain: A comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686-1696.
7. Attia E, Kaplan AS, Walsh BT, Gershkovich M, Yilmaz Z, Musante D, Wang Y,. Olanzapine versus placebo for out-patients with anorexia nervosa. Psychol Med 2011; 41: 2177-2182.
8. Hagman J, Gralla J, Sigel E, Ellert S, Dodge M, Gardner R, et al. A double-blind, placebo-controlled study of risperidone for the treatment of adolescents and young adults with anorexia nervosa: A pilot study. J Am Acad Child Adolesc Psychiatry 2011; 50: 915-924.
9. Crow SJ, Mitchell JE, Roerig JD, Steffen K,. What potential role is there for medication treatment in anorexia nervosa? Int J Eat Disord 2009; 42: 1-8.
10. Gaebel W, Möller H-J, Buchkremer G, Ohmann C, Riesbeck M, Wölwer W, et al. Pharmacological long-term treatment strategies in first episode schizophrenia: Study design and preliminary results of an ongoing RCT within the German Research Network on Schizophrenia. Eur Arch Psychiatry Clin Neurosci 2004; 254: 129-140.
11. McGlashan T, Zipursky R, Perkins D, Addington J, Miller T, Woods S, et al. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 2006; 163: 790-799.
12. Schooler N, Rabinowitz J, Davidson M, Emsley R, Harvey P, Kopala L, et al. Risperidone and haloperidol in first-episode psychosis: A long-term randomized trial. Am J Psychiatry 2005; 162: 947-953.
13. Ananth J, Parameswaran S, Gunatilake S,. Side effects of atypical antipsychotic drugs. Curr Pharm Des 2004; 10: 2219-2229.
14. Kafantaris V, Leigh E, Hertz S, Berest A, Schebendach J, Sterling WM, et al. A placebo-controlled pilot study of adjunctive olanzapine for adolescents with anorexia nervosa. J Child Adolesc Psychiatr Ment Health Nurs 2011; 21: 207-212.
15. Van Wymelbeke V, Brondel L, Brun J, Rigaud D,. Factors associated with the increase in resting energy expenditure during refeeding in malnourished anorexia nervosa patients. Am J Clin Nutr 2004; 80: 1469-1477.
16. Alvarez P, Pahissa J,. QT alterations in psychopharmacology: Proven candidates and suspects. Curr Drug Saf 2010; 5: 97-104.
17. DerSimonian R, Laird N,. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
18. Higgins JP, Thompson SG,. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-1558.
19. Altman DG, Bland JM,. Interaction revisited: The difference between two estimates. BMJ 2003; 326: 219.
20. Brambilla F, Monteleone P, Maj M,. Olanzapine-induced weight gain in anorexia nervosa: Involvement of leptin and ghrelin secretion? Psychoneuroendocrinology 2007; 32: 402-406.
21. Brambilla F, Garcia CS, Fassino S, Daga GA, Favaro A, Santonastaso P, et al. Olanzapine therapy in anorexia nervosa: Psychobiological effects. Int Clin Psychopharmacol 2007; 22: 197-204.
22. Bissada H, Tasca GA, Barber AM, Bradwejn J,. Olanzapine in the treatment of low body weight and obsessive thinking in women with anorexia nervosa: A randomized, double-blind, placebo-controlled trial. Am J Psychiatry 2008; 165: 1281-1288.
23. Mondraty N, Birmingham CL, Touyz S, Sundakov V, Chapman L, Beumont P,. Randomized controlled trial of olanzapine in the treatment of cognitions in anorexia nervosa. Australas Psychiatry 2005; 13: 72-75.
24. Ruggiero GM, Laini V, Mauri MC, Ferrari VM, Clemente A, Lugo F, et al. A single blind comparison of amisulpride, fluoxetine and clomipramine in the treatment of restricting anorectics. Prog Neuropsychopharmacol Biol Psychiatry 2001; 25: 1049-1059.
25. Dunican K, DelDotto D,. The role of olanzapine in the treatment of anorexia nervosa. Ann Pharmacother 2007; 41: 111-115.
26. Toren P, Ratner S, Laor N, Weizman A,. Benefit-Risk Assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents. Drug Saf 2004; 27: 1135-1156.
27. McKnight RF, Park RJ,. Atypical antipsychotics and anorexia nervosa: A review. Eur Eat Disord Rev 2010; 18: 10-21.